SOUTH SAN FRANCISCO, CA, 3T Biosciences today announced its launch from stealth backed by a $40 million Series A financing round.
3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced its launch from stealth backed by $40 million Series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. As part of its launch, 3T announced it has exclusively in-licensed from Stanford University a precise antibody-based peptide-HLA therapeutic discovery platform and development-stage MAGE-A3 T-cell receptor (TCR)-T assets to rapidly expand 3T's therapeutic portfolio.
3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach. 3T Biosciences' 3T-TRACE platform technology is designed to overcome the challenges of advancing T-cell receptor (TCR)-based therapeutics.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about